Lycia Therapeutics director has options on 57,666 shares

The option award has monthly vesting after the initial installment, subject to continued service on each vesting date.

Rhea-AI Filing Summary

Lycia Therapeutics, Inc. director Jane Henderson reported directly held stock options covering 57,666 shares of common stock, with an exercise price of $3.70 per share and an expiration date of August 10, 2036. The options vested as to 1/48 of the award on August 6, 2026; an additional 1/48 will vest monthly thereafter, subject to Jane Henderson providing service on each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Henderson Jane

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) F1	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 57,666 contracts (Direct)

Footnotes (1)

1. F1. The options vested as to 1/48 of the total award on August 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Shares underlying stock options: 57,666 shares Exercise price: $3.70 per share Initial vesting: 1/48 of the award +1 more

4 metrics

Shares underlying stock options 57,666 shares Direct stock options reported for Jane Henderson

Exercise price $3.70 per share Jane Henderson's stock options

Initial vesting 1/48 of the award Vested on August 6, 2026

Expiration date August 10, 2036 Jane Henderson's stock options

Key Terms

Stock Option (Right to Buy), exercise price, vested

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

exercise price financial

"options with an exercise price of $3.70 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vested financial

"The options vested as to 1/48 of the total award"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LYCA shares are covered by Jane Henderson's stock options?

Jane Henderson's options cover 57,666 shares of common stock at an exercise price of $3.70 per share. The options expire on August 10, 2036.

What is the vesting schedule for Jane Henderson's LYCA options?

The options vested as to 1/48 of the award on August 6, 2026. An additional 1/48 will vest monthly thereafter, subject to Jane Henderson providing service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/24/2026 - 08:14 PM EDT Accepted by SEC EDGAR 10/22/2026 - 07:21 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Henderson Jane

(Last) (First) (Middle)

C/O LYCIA THERAPEUTICS, INC.

400 EAST JAMIE COURT, SUITE 200

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/22/2026

3. Issuer Name and Ticker or Trading Symbol
Lycia Therapeutics, Inc. [ LYCA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	08/10/2036	Common Stock	57,666	$3.7	D

Explanation of Responses:

1. The options vested as to 1/48 of the total award on August 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Amy Bachrodt, Attorney-in-Fact	10/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)